Citations 1
Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications
Maity, Surjendu , Bhuyan, Tamanna , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Najafabadi, Alireza Hassani , Chen, Junjie , Yilgor, Can , Choroomi, Auveen, Torres, Emily, Mecwan, Marvin , Wang, Zhaohui , Quiñones‐Hinojosa, Alfredo , Jucaud, Vadim , Dokmeci, Mehmet R. , Kawakita, Satoru , Sharma, Saurabh , Nguyen, Huu Tuan , Hassani Najafabadi, Alireza , Khorsandi, Danial , Yilgor, Can , Moniz-Garcia, Diogo, Jucaud, Vadim , Dokmeci, Mehmet Remzi , Khademhosseini, Ali , Jewell, Christopher M. , Ermis, Menekşe , Falcone, Natashya , Mandal, Kalpana , Torres, Emily, John, Johnson V. , Akbari, Mohsen , Moniz‐Garcia, Diogo , Khademhosseini, Ali
Small | November 13, 2024 | Volume: 21 | Issue: 1 | Pages: No page available
Abstract Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ‐on‐a‐chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM‐on‐a‐chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM‐on‐a‐chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM‐on‐a‐chip models.